BioSpace News Archive

Foghorn Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, announced that the first patient has been dosed in a first-in-human clinical trial of FHD-609, which is being developed as a treatment for synovial sarcoma.

GT Biopharma, Inc., a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer cell engager, TriKE® protein biologic technology platform, announced the promotion of Gregory Berk, M.D., to the position of President of Research & Development and Chief Medical Officer.

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, announced it has achieved a milestone in its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent® technologies around the world.

Samyang Biopharm USA, Inc. a global biotech subsidiary of the Samyang Holdings Pharmaceuticals Corp., announced that the company has entered into a three-year research collaboration with Dr. Hyun-Sung Lee, Assistant Professor of Surgery and Director of the Systems Onco-Immunology Laboratory at Baylor College of Medicine.

Bavarian Nordic A/S announced that the Company has entered a funding agreement with the Danish Ministry of Health to further advance the development of ABNCoV2, the Company’s COVID-19 vaccine candidate.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), announced today it has established a formal research collaboration with the Boston-based Angiogenesis Foundation, a prestigious independent scientific organization focused on driving innovations in health promotion, disease prevention, and disease treatment.

PetVivo Holdings, Inc. an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that the Company has changed the brand name of its therapeutic osteoarthritis and lameness product to “SPRYNG”.

According to the report, the global vessel sealing devices market was valued over US$ 4.21 Bn in 2020, and it is projected to expand at a CAGR of 5.2% from 2021 to 2031.

According to the report, the global short bowel syndrome market was valued at US$ 728.3 Mn in 2020 and is projected to expand at a CAGR of 15.9% from 2021 to 2031.